Aequus Pharmaceuticals Inc (AQS) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.003x

Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-21.22K ≈ $-15.35K USD) by net assets (CA$-6.89 Million ≈ $-4.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Aequus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Aequus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AQS total liabilities for a breakdown of total debt and financial obligations.

Aequus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
CML Microsystems Plc
LSE:CML
0.030x
Foncière 7 investissement Société Anonyme
PA:LEBL
0.140x
Craven House Capital PLC
LSE:CRV
0.000x
Upsellon Brands Holdings Ltd
TA:CHR
0.180x
Time Out Group plc
LSE:TMO
0.025x
Gelion PLC
LSE:GELN
-0.175x
Time Finance PLC
LSE:TIME
-0.009x
TCTM Kids IT Education Inc.
NASDAQ:VSA
N/A

Annual Cash Flow Conversion Efficiency for Aequus Pharmaceuticals Inc (2013–2024)

The table below shows the annual cash flow conversion efficiency of Aequus Pharmaceuticals Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see AQS market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CA$-6.45 Million
≈ $-4.67 Million
CA$-1.66 Million
≈ $-1.20 Million
0.257x -51.98%
2023-12-31 CA$-4.29 Million
≈ $-3.11 Million
CA$-2.29 Million
≈ $-1.66 Million
0.534x -62.24%
2022-12-31 CA$-1.38 Million
≈ $-998.30K
CA$-1.95 Million
≈ $-1.41 Million
1.415x +315.94%
2021-12-31 CA$1.79 Million
≈ $1.29 Million
CA$-1.17 Million
≈ $-847.96K
-0.655x +53.28%
2020-12-31 CA$573.95K
≈ $415.19K
CA$-804.91K
≈ $-582.26K
-1.402x -175.50%
2019-12-31 CA$-877.09K
≈ $-634.48K
CA$-1.63 Million
≈ $-1.18 Million
1.857x +221.37%
2018-12-31 CA$1.68 Million
≈ $1.22 Million
CA$-2.57 Million
≈ $-1.86 Million
-1.530x +7.45%
2017-12-31 CA$2.31 Million
≈ $1.67 Million
CA$-3.81 Million
≈ $-2.76 Million
-1.654x +53.13%
2016-12-31 CA$1.27 Million
≈ $915.58K
CA$-4.47 Million
≈ $-3.23 Million
-3.528x -18.07%
2015-12-31 CA$1.28 Million
≈ $929.30K
CA$-3.84 Million
≈ $-2.78 Million
-2.988x -539.59%
2014-12-31 CA$2.92 Million
≈ $2.11 Million
CA$-1.36 Million
≈ $-987.33K
-0.467x +85.04%
2013-12-31 CA$280.60K
≈ $202.98K
CA$-876.06K
≈ $-633.73K
-3.122x --

About Aequus Pharmaceuticals Inc

V:AQS Canada Drug Manufacturers - Specialty & Generic
Market Cap
$479.73K
CA$663.17K CAD
Market Cap Rank
#30557 Global
#1646 in Canada
Share Price
CA$0.01
Change (1 day)
+0.00%
52-Week Range
CA$0.01 - CA$0.01
All Time High
CA$0.69
About

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more